What are the causes of vaginal dryness?
At the time of menopause or pre menopause, the levels of Oestrogen in your body drop significantly. This has an impact on collagen synthesis and Hyaluronic acid, which are respectively responsible for the thickness and elasticity of the tissues and vaginal mucosa moisturisation. Subsequently, vaginal atrophy (the vaginal walls are thinning, drying) and an inflammation of the tissues can occur. Medical professionals cause this phenomenon the Genitourinary Syndrome of Menopause (GSM).
Genitourinary syndrome of menopause
Symptoms of Genitourinary syndrome of menopause can include:
- Vaginal dryness
- Chronic irritation and itching
- Burning with urination
- Discomfort or pain with intercourse
- Light bleeding after intercourse
These symptoms can deeply affect your wellbeing and sexual health and should be considered seriously by health practitioners.
If you are experiencing one or several of those symptoms, then you could be eligible for this non-surgical, quick and effective treatment.
What is the treatment?
DESIRIAL® is the first type of injectable hyaluronic acid to be CE certified (since 2011) in Europe and registered with the authorities for gynaecological indications (vaginal mucosa rejuvenation).
The gel is composed of cross-linked Hyaluronic Acid that will keep the tissues hydrated for a minimum of 6 months. An antioxidant, Mannitol, was also added to the formula, to protect the Hyaluronic Acid penetrating the tissues at the moment of injection.
After applying a local anaesthetic for optimal comfort, DESIRIAL® is injected superficially at the entrance of the vagina with the aim of softening and deeply hydrating tissues. One session lasts between 20 and 40 min.
How many sessions are required?
Depending on your body and symptoms, the number of necessary sessions can vary, but studies show that results are noticeable after one session. Come and have a chat with us over a coffee and we will work out your personal treatment plan.
What are the contraindications for this type of treatment?
DESIRIAL® will not be suitable to you if:
● You have a tendency for developing hypertrophic scars
● You have a known hypersensitivity to one of the ingredients (hyaluronic acid, mannitol)
● You are presenting clinical signs of inflammation and/or infection of bacterial, fungal (e.g. thrush) or viral (e.g. papilloma, herpes) origin and/or if you are following treatment for one of these pathologies
Are there any side effects for this type of treatment?
After an intimate care injection, and just like with all other hyaluronic acid-based injections, you may experience some swelling, bruising, irritation or sensitivity at the injection site. These side effects will generally disappear after several days. You should contact us back if these undesirable effects continue for more than a week.
What our patients said about DESIRIAL®…
“These are the best facilities that I have visited for my company medical. The staff and doctors are very friendly and efficient.”
– R.L – Health Screen
“Clean and neat clinic. Beautiful facilities and great services. Thank you!”
– E.D – GP Consultation
“Lovely care and attention from all staff. We always feel very looked after – thank you.”
– C.V – GP Consultation
– E.N – Iron Infusion
– T.G – Hormone Consultation
– L.W – GP Consultation
“Very good service. The Surgery is clean, the service was prompt, the Doctor was very informative and the staff were friendly and professional.”
– A.S – Minor Surgery
“The doctor and assistant were both sympathetic and nice. Very sweet and attentive.”
– M.M – GP Consultation
“I had an excellent service- reception were able to get me a last minute appointment. We were welcomed in an efficient, professional manner.”
– F.A.M – GP Consultation
– T.S – Vaccination
– T.C – Regenerative Consultation
– H.G – Vaccination
– L.R – GP Consultation
 (Non-interventional, uncontrolled, open-label prospective trial evaluating the efficacy and tolerance of Desirial® in their indications for use. Visits after 1 month, 3 months, 6 months and 12 months post-injection. The study was carried out on 87 patients (52 patients received Desirial®).
 Berreni, N., Salerno, J., Chevalier, T. et al. Evaluation of the effect of multipoint intra-mucosal vaginal injection of a specific cross-linked hyaluronic acid for vulvovaginal atrophy: a prospective bi-centric pilot study. BMC Women’s Health 21, 322 (2021). https://doi.org/10.1186/s12905-021-01435-w